Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004137 · ClinicalTrials.gov registry record · Phase 2
S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 20
- Study locations
NCT00004137 is a Phase 2 study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 88 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00004137, a Phase 2 study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have previously untreated extensive-stage small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- DRUG topotecan hydrochloride
Study Locations (20)
California
- Veterans Affairs Medical Center - Long Beach - Long Beach
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Beckman Research Institute, City of Hope - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Medical Center - Sacramento
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- David Grant Medical Center - Travis Air Force Base
Arizona
- CCOP - Greater Phoenix - Phoenix
- Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Colorado
- Veterans Affairs Medical Center - Denver - Denver
- University of Colorado Cancer Center - Denver
Alabama
- MBCCOP - Gulf Coast - Mobile
Georgia
- CCOP - Atlanta Regional - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 1999-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004137
The ClinicalTrials.gov registry entry for NCT00004137 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00004137 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00004137 about?
NCT00004137 is a clinical study titled "S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blo...
What is the current status of trial NCT00004137?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 1999-10. Estimated completion is 2008-11.
What conditions does trial NCT00004137 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00004137?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004137?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004137 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.